HAEMONETICS CORP — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Haemonetics amended its 2019 Long-Term Incentive Compensation Plan (Board: June 9, 2026; Stockholders: July 24, 2026) and 2007 Employee Stock Purchase Plan (Board: May 15, 2026; Stockholders: July 24, 2026). Key changes: LTIP added 4,680,000 shares to reserve, extended 10-year term, established fungible ratio (2.76:1 for non-option awards). ESPP extended through Dec 31, 2036, adjusted compensation definitions. Separately, Martin Madaus (ex-CEO Ortho Clinical Diagnostics, Millipore; board chair Repligen) elected to Board July 24, 2026. No counterparty dollar amounts, specific termination fees, or material financial impacts disclosed.
Why this rating
Routine equity plan amendments with standard administrative updates; board appointment adds experienced healthcare exec but is typical governance. Immaterial to $2.2B company.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.